FDMT · 4D Molecular Therapeutics, Inc.
$9.61
-0.24 (-2.44%)
At close · Jul 29
Market Cap
$681.74M
Shares
69.21M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$85.21M
+230194.6%
FY2025
Net Income
-$140.11M
+12.9%
FY2025
Operating Margin
-187.24%
+507491.1pp
FY2025
Diluted EPS
-$2.42
+18.8%
FY2025
Operating Cash Flow
-$109.08M
+18.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $88.24M | $85.21M | $37K | $20.72M | $3.13M | $18.04M | $13.61M | $6.99M | |
| $219.98M | $195.7M | $141.3M | $97.1M | $80.25M | $61.36M | $53.04M | $38.72M | |
| $47.81M | $49.06M | $46.58M | $36.49M | $32.91M | $28.01M | $17.24M | $13.9M | |
| — | $4.69M | $4.65M | $4.2M | $2.4M | $1.52M | $1.44M | $1M | |
| $267.79M | $244.76M | $187.88M | $133.59M | $113.16M | $89.37M | $70.28M | $57.75M | |
| -$179.55M | -$159.55M | -$187.84M | -$112.87M | -$110.03M | -$71.33M | -$56.66M | -$50.76M | |
| — | -187.24% | -507678.38% | -544.65% | -3516.52% | -395.46% | -416.28% | -726.65% | |
| — | -$154.85M | -$183.19M | -$108.66M | -$107.63M | -$69.81M | -$55.22M | -$49.76M | |
| $18.76M | $19.48M | $27.05M | $12.21M | $2.57M | $137K | $152K | $1.5M | |
| $18.65M | $19.44M | $26.97M | $12.03M | $2.54M | $16K | -$29K | $1.46M | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$160.9M | -$140.11M | -$160.87M | -$100.84M | -$107.49M | -$71.32M | -$56.69M | -$49.31M | |
| — | -164.43% | -434778.38% | -486.59% | -3435.41% | -395.37% | -416.49% | -705.78% | |
| -$161.41M | -$139.61M | -$160.66M | -$99.63M | -$108.27M | -$71.74M | -$56.69M | — | |
| USD/shares | — | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.57 | — | — |
| USD/shares | — | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.57 | — | — |
| shares | — | 57.93M | 53.94M | 39.13M | 32.35M | 27.73M | 6.43M | 5.14M |
| shares | — | 57.93M | 53.94M | 39.13M | 32.35M | 27.73M | 6.43M | 5.14M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.45×
EV/EBIT
—
Peer median 24.46×
P/E (TTM)
—
Peer median 9.81×
Peer medians compare against the 303 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Japan | $85,000,000 | $0 | — | — | — | — | — |
| United States | $209,000 | $37,000 | $20,156,000 | $35,000 | $121,000 | -$27,000 | $666,000 |
| Australia | — | — | — | — | — | — | $7,000 |
| Switzerland | — | — | — | — | $17,181,000 | $12,897,000 | $6,287,000 |
| Netherlands | — | — | $567,000 | $3,094,000 | $736,000 | $742,000 | $26,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Collaboration and License Revenue | $85,209,000 | $37,000 | $20,723,000 | $3,129,000 | $18,038,000 | $13,612,000 | $6,986,000 |
Key facts
CIK
1650648
CUSIP
35104E100
13F (30d)
22 filings
22 filers
Visit website
Investor relations